Keith Barr - 16 Mar 2026 Form 4 Insider Report for CARMAX INC (KMX)

Role: President and CEO, Director
Signature: Christine Carter, attorney-in-fact
Issuer symbol: KMX
Transactions as of: 16 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 18 Mar 2026, 16:10:35 UTC
Previous filing: 09 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Barr Keith	President and CEO, Director	12800 TUCKAHOE CREEK PARKWAY, RICHMOND	Christine Carter, attorney-in-fact	18 Mar 2026	0001798472

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KMX	Common Stock	Award		+23,975		$0.000000^*	23,975	16 Mar 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KMX	Stock Options (Right to Buy)	Award		+54,025		$0.000000^*	54,025	16 Mar 2026	Common Stock	54,025	$41.71	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock options were granted in tandem with stock appreciation rights (SARS). Accordingly, the exercise of one results in the surrender to the Company of the other. The SARS become exercisable only following a change in control of the Company as set forth in the Company's 2002 Stock Incentive Plan, as amended and restated. Once exercisable, the SARS would entitle the Reporting Person to receive the cash value of the options in lieu of exercising the options.
F2	The stock options become exercisable with respect to one-fourth of the underlying shares of Common Stock on each of March 16, 2027, March 16, 2028, March 16, 2029, and March 16, 2030.

Content

The stock options were granted in tandem with stock appreciation rights (SARS). Accordingly, the exercise of one results in the surrender to the Company of the other. The SARS become exercisable only following a change in control of the Company as set forth in the Company's 2002 Stock Incentive Plan, as amended and restated. Once exercisable, the SARS would entitle the Reporting Person to receive the cash value of the options in lieu of exercising the options.

The stock options become exercisable with respect to one-fourth of the underlying shares of Common Stock on each of March 16, 2027, March 16, 2028, March 16, 2029, and March 16, 2030.